Darrell King Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Darrell King reduced its stake in Pfizer by 10.99% during the most recent quarter end. The investment management company now holds a total of 15,550 shares of Pfizer which is valued at $543,939 after selling 1,919 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Pfizer makes up approximately 0.10% of Darrell King’s portfolio.

Other Hedge Funds, Including , Fmr reduced its stake in PFE by selling 13,624,614 shares or 34.34% in the most recent quarter. The Hedge Fund company now holds 26,045,576 shares of PFE which is valued at $911,074,248. Pfizer makes up approx 0.12% of Fmr’s portfolio.Bryn Mawr Trust Co reduced its stake in PFE by selling 2,702 shares or 0.83% in the most recent quarter. The Hedge Fund company now holds 321,448 shares of PFE which is valued at $11,244,251. Pfizer makes up approx 0.69% of Bryn Mawr Trust Co’s portfolio.Klingman Associates reduced its stake in PFE by selling 156 shares or 0.82% in the most recent quarter. The Hedge Fund company now holds 18,860 shares of PFE which is valued at $668,398. Pfizer makes up approx 0.21% of Klingman Associates’s portfolio.Intrust Bank Na boosted its stake in PFE in the latest quarter, The investment management firm added 60 additional shares and now holds a total of 65,833 shares of Pfizer which is valued at $2,323,247. Pfizer makes up approx 0.92% of Intrust Bank Na’s portfolio.Gilman Hill Asset Management boosted its stake in PFE in the latest quarter, The investment management firm added 3,014 additional shares and now holds a total of 152,650 shares of Pfizer which is valued at $5,608,361. Pfizer makes up approx 2.22% of Gilman Hill Asset Management’s portfolio.

Pfizer opened for trading at $35 and hit $35.27 on the upside on Tuesday, eventually ending the session at $35.09, with a gain of 0.72% or 0.25 points. The heightened volatility saw the trading volume jump to 1,69,57,889 shares. Company has a market cap of $212,844 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *